These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 10315418)

  • 21. [Early pregnancy serum screening in Helsinki: results and mothers' opinions].
    Salonen R; Turpeinen U; Kurki L; Lappalainen M; Ammälä P; Hiilesmaa V; Teramo K; von Koskull H; Gahmberg N; Stenman UH
    Duodecim; 1997; 113(24):2548-55. PubMed ID: 10892162
    [No Abstract]   [Full Text] [Related]  

  • 22. Screening for open neural tube defects from 21 to 25 weeks' gestation: the Manitoba experience.
    Björklund NK; MacDonald KM; Evans JA; Schneider CE; Chodirker BN
    Prenat Diagn; 2005 Aug; 25(8):715-7. PubMed ID: 16052469
    [No Abstract]   [Full Text] [Related]  

  • 23. Very low alpha-fetoprotein in Down syndrome maternal serum screening.
    Muller F; Dreux S; Sault C; Galland A; Puissant H; Couplet G; Lemay C; Larcher ME; Renom G;
    Prenat Diagn; 2003 Jul; 23(7):584-7. PubMed ID: 12868089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening and diagnosis of fetal neural tube defects, abdominal wall defects and Down's syndrome. With special reference to biochemical and ultrasound screening in the second trimester of pregnancy and to early amniocentesis.
    Jørgensen FS
    Dan Med Bull; 2001 Aug; 48(3):127-45. PubMed ID: 11556264
    [No Abstract]   [Full Text] [Related]  

  • 25. Sequential pathways of testing after first-trimester screening for trisomy 21.
    Platt LD; Greene N; Johnson A; Zachary J; Thom E; Krantz D; Simpson JL; Silver RK; Snijders RJ; Goetzl L; Pergament E; Filkins K; Mahoney MJ; Hogge WA; Wilson RD; Mohide P; Hershey D; MacGregor S; Bahado-Singh R; Jackson LG; Wapner R;
    Obstet Gynecol; 2004 Oct; 104(4):661-6. PubMed ID: 15458882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biochemical screening for chromosomal disorders and neural tube defects (NTD): is adjustment of maternal alpha-fetoprotein (AFP) still appropriate in insulin-dependent diabetes mellitus (IDDM)?
    Sancken U; Bartels I
    Prenat Diagn; 2001 May; 21(5):383-6. PubMed ID: 11360279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The ABCs of pre-, neo-, and post-natal testing.
    Grenache DG; Karon B; Ernst D
    MLO Med Lab Obs; 2009 Sep; 41(9):10, 12, 14-8 passim; quiz 22-3. PubMed ID: 19877396
    [No Abstract]   [Full Text] [Related]  

  • 28. FDA study finds test kits effective in spotting birth defects.
    Public Health Rep; 1998; 113(5):382. PubMed ID: 9769758
    [No Abstract]   [Full Text] [Related]  

  • 29. Second trimester serum markers.
    Canick JA; MacRae AR
    Semin Perinatol; 2005 Aug; 29(4):203-8. PubMed ID: 16104669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Second-trimester maternal serum screening for Down syndrome in Mainland China.
    Liao C; Huang Y; Li D; Song S; Yi C; Zhou J
    Prenat Diagn; 2006 Dec; 26(13):1271-2. PubMed ID: 17139699
    [No Abstract]   [Full Text] [Related]  

  • 31. [Screening by maternal serum markers for Down's syndrome].
    Liu JT; Hao N; Sun NH; Wang FY; Xu YH; Gai MY; Bian XM; Yang JQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Apr; 25(2):156-9. PubMed ID: 12905710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A cost-effectiveness analysis of prenatal screening strategies for Down syndrome.
    Odibo AO; Stamilio DM; Nelson DB; Sehdev HM; Macones GA
    Obstet Gynecol; 2005 Sep; 106(3):562-8. PubMed ID: 16135588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Down's syndrome risk estimates demonstrate considerable heterogeneity despite homogeneity of input.
    Reynolds T; Ellis A; Jones R
    Ann Clin Biochem; 2004 Nov; 41(Pt 6):464-8. PubMed ID: 15588435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prenatal screening tests facilitate risk assessment.
    Miller SM; Isabel JM
    MLO Med Lab Obs; 2002 Feb; 34(2):8-11, 14-6, 19; quiz 20-1. PubMed ID: 11881274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Trisomy 21 screening: value of ultrasound and serum markers in a combined approach].
    Senat MV; Rozenberg P; Bernard JP; Ville Y
    J Gynecol Obstet Biol Reprod (Paris); 2001 Feb; 30(1):11-27. PubMed ID: 11240502
    [No Abstract]   [Full Text] [Related]  

  • 36. Prenatal screening and diagnosis for pediatricians.
    Cunniff C;
    Pediatrics; 2004 Sep; 114(3):889-94. PubMed ID: 15342871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Second trimester two-step trisomy 18 screening using maternal serum markers.
    Muller F; Sault C; Lemay C; Roussel-Mizon N; Forestier F; Frendo JL;
    Prenat Diagn; 2002 Jul; 22(7):605-8. PubMed ID: 12124697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Second-trimester prenatal screening for Down syndrome and the relationship of maternal serum biochemical markers to pregnancy complications with adverse outcome.
    Spencer K
    Prenat Diagn; 2000 Aug; 20(8):652-6. PubMed ID: 10951476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Down syndrome maternal serum marker screening after 18 weeks' gestation.
    Muller F; Dreux S; Oury JF; Luton D; Uzan S; Uzan M; Levardon M; Dommergues M
    Prenat Diagn; 2002 Nov; 22(11):1001-4. PubMed ID: 12424764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The routinization of prenatal testing.
    Suter SM
    Am J Law Med; 2002; 28(2-3):233-70. PubMed ID: 12197464
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.